Systemic Antibiotics Market - Introduction
Antibiotics are indispensable medicines for the treatment of life-threatening disorders and infections. Systemic antibiotics are antibiotics used in the treatment of bacterial infections, administered orally or intravenously i.e., directly into the blood stream of patients. Systemic antibiotics work throughout the body and help in resolution of infections.
Systemic antibiotics are used to treat urinary tract infections, skin infections, dental diseases, and other bacterial infections. Amoxicillin, cephalosporin, macrolide, tetracycline, and metronidazole are major systemic antibiotics used for the treatment of dental disorders including periodontal and endodontic diseases. Moreover, tetracycline class of antibiotics are considered first-line therapy for severe acne which work by inhibiting the protein synthesis by binding the 30S subunit of the bacterial ribosome. Furthermore, macrolides such as azithromycin and erythromycin are used for the treatment of acne.
Identify the key factors that will drive your company’s growth. Request a brochure of this report here
Systemic Antibiotics Market – Competitive Landscape
- In June 2019, Merck & Co. Inc. received U.S. Food and Drug Administration (FDA) approval for ZERBAXA for the treatment of adults with hospital-acquired bacterial infections.
- In June 2017, Melinta Therapeutics received U.S. Food and Drug Administration (FDA) approval for its drug Baxelda. The new drug is available as an injectable and oral tablet form for the treatment of patients with acute bacterial skin or skin structure infections (ABSSSI).
Founded in 2000, GlaxoSmithKline is a leading firm involved in developing and manufacturing of innovative consumer healthcare products, vaccines, and pharmaceutical medicines. The company focuses on research activities for the development of novel systemic antibiotics for the treatment of gram-negative bacterial infections.
Merck & Co., Inc.
Incorporated in 1970, Merck & Co., Inc. is based in Kenilworth, New Jersey. Merck & Co., Inc. is a global health care provider primarily engaged in delivering innovative health solutions through vaccines, prescription medicines, animal health products, and biological therapies. The company invests in research and development (R&D) of infectious diseases to address unmet medical needs of patients. The firm operates in more than 140 countries to deliver novel health solutions.
Melinta Therapeutics, Inc.
Established in 2000, Melinta Therapeutics, Inc. is a leading pharmaceutical company engaged in manufacture and commercialization of differentiated anti-infectives for hospital and other healthcare settings. The company focuses on partnership with leading pharmaceutical companies for distribution of Baxdela in regions based outside the U.S. For instance, the firm has partnered with Eurofarma Laboratories S.A. for distribution of its drug in Central and South America and with Menarini for distribution in Europe and Asia-Pacific countries excluding Japan.
Other prominent players operating in the global systemic antibiotics market are Pfizer, Inc., Bayer Healthcare AG, Cubist Pharmaceuticals, AstraZeneca, MerLion Pharmaceuticals Pte Ltd., and Johnson & Johnson. These players have adopted organic and in-organic growth strategies to expand product portfolio and strengthen market foothold. Moreover, innovation of new antibiotics by leading industry players targeting gram-negative bacteria is expected to effectively combat antibiotic resistance and drive the global market in the next few years.
Expanding operations in future? To get the perfect launch ask for a custom report here
Systemic Antibiotics Market - Dynamics
Rise in Prevalence of Chronic Diseases Globally Drives Market
Increase in incidence of infectious and chronic diseases and rise in prevalence of dental disorders are the major factors driving the global systemic antibiotics market. Periodontal diseases and tooth loss and decay are highly common dental disorders across the globe. For instance, it is estimated that periodontal disease is highly prevalent in the geriatric population and affects 20% to 50% of the population globally. Moreover, diabetic mellitus leading to diabetic foot infections, urinary tract infections, and other contagious diseases is rising across the globe. This is projected to fuel the demand for systemic antibiotics in the next few years. Rise in skin infections and other chronic wounds is likely to boost demand for systemic antibiotics during the forecast period.
Favorable Government Initiatives and Increase in Investment in R&D Propels Market
Increase in investment in research and development for new drug development is anticipated to augment the global systemic antibiotics market during the forecast period. For instance, the U.S. invested US$ 260 Mn and US$ 410 Mn in antibiotic R&D activities in 2015 and 2016, respectively.
Moreover, launch and implementation of various government initiatives such as antibiotic stewardship by CDC to promote the appropriate use of antibiotics and reduce antimicrobial resistance is expected to augment the global systemic antibiotics market during the forecast period.
Adverse Reactions and Antibiotic Resistance to Impede the Systemic Antibiotics Market
Emergence of antibiotic resistance by various species of bacteria and adverse reactions including allergic reactions, hypersensitivity reactions, anaphylaxis, and rashes associated with intake of systemic antibiotics are expected to restrain the global market in the near future. For instance, tinnitus, dizziness, pigment deposition of skin, pharyngitis, gastrointestinal disturbances, C. difficile infection, photosensitivity caused due to tetracycline, and macrolides during acne treatment are anticipated to hamper the growth of the global systemic antibiotics market in the next few years.
North America to Dominate the Systemic Antibiotics Market
Increase in incidence of diabetes mellitus leading to diabetic foot infections in the U.S. is a major factor contributing to the dominant share of North America during the forecast period. Based on National Diabetes Statistics Report 2017 by CDC, 30.3 million people in the U.S. have diabetes. According to the American Diabetes Association (ADA), annual incidence of foot ulcers in diabetes patients ranges from 2% to 8% in the U.S. Furthermore, strong pipeline of antibiotics is anticipated to drive the market in the U.S. in the next few years. According to the World Health Organization (WHO), there were around 39 systemic antibiotics in varying clinical development phases in the U.S. in 2015. All these factors are anticipated to drive the market in North America.
Systemic Antibiotics Market – Segmentation
The systemic antibiotics market can be segmented based on:
- Drug Class
- Distribution Channel
Systemic Antibiotics Market Segmentation – By Drug Class
In terms of drug class, the systemic antibiotics can be categorized into:
Systemic Antibiotics Market Segmentation – By Indication
Based on indication, the global systemic antibiotics market can be divided into:
- Urinary Tract Infections
- Respiratory Tract Infections
- Skin or Soft Tissue Infection
- Dental Disorders
- Diabetic Foot Infections
Systemic Antibiotics Market Segmentation – By Distribution Channel
In terms of distribution channel, the global systemic antibiotics market can be classified into:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.